Janus Living (JAN) Sold 30.2M Shares at $28.50 in November 2026; Healthpeak Keeps About 63%
Some links pay us a referral fee; each one says so. Disclosure
Filing alert · free
An email when Janus Living files with the SEC
An email the day Janus Living files something new, with the link to the document on the SEC site.
Quick answer
As of November 20, 2026, Janus Living, Inc. (NYSE: JAN, SEC CIK 2100805), the senior housing REIT that Healthpeak listed in March 2026, has closed its fourth stock sale: 30,187,500 Class A-1 shares at $28.50 on November 6, 2026, including the underwriters' full option (Form 8-K, accession 0001104659-26-123853). The prospectus filed November 5, 2026 (0001104659-26-123373) was for 26,250,000 shares and estimated net proceeds of about $719 million, or $827 million with the option. It was not the IPO: the IPO priced at $20.00 in March 2026. Healthpeak sold nothing. Before the sale it held 138,816,246 Class A-1 shares and 75,917,780 operating units and had 63.8% of the votes; with the option exercised that is about 63.1% of shares plus units (our arithmetic). Q3 2026 FFO as Adjusted was $75.8 million against $36.8 million a year earlier (Form 10-Q, accession 0001628280-26-069530, and the 424B4), and the monthly dividend is $0.0475, $0.57 a year.
Key takeaways
- The November sale is the fourth, not the first. Janus sold 48.3 million shares at $20.00 in March 2026 ($966 million gross), 28.75 million at $25.00 in June ($719 million), 18.4 million at $29.00 in August ($534 million) and 30,187,500 at $28.50 in November (about $860.3 million, our arithmetic). The four add up to about $3.08 billion of gross proceeds (our arithmetic).
- Healthpeak sold no shares in any of them. All shares were sold by Janus. Healthpeak's Schedule 13G showed 214,734,026 shares and units, 81.6% as reported, at March 31, 2026; after November it is about 63.1% of shares plus units (our arithmetic). It keeps control: the prospectus says Healthpeak affiliates own a majority of the voting power.
- Healthpeak cannot sell until March 2027. The lock-up on Healthpeak, the manager and officers runs 365 days after March 19, 2026, which is March 19, 2027 (our arithmetic), unless BofA Securities and J.P. Morgan consent; the banks say they have no present intent to release shares. Healthpeak also holds registration rights over 214,734,026 shares.
- The numbers grew by buying. Janus owned 74 senior housing communities with 15,256 units in 19 states at September 30, 2026, and 41 of them were acquired in 2026 for $2.26 billion. Q3 2026 Adjusted NOI was $75.6 million against $41.8 million; same-store Adjusted NOI rose 25.9% on 15 communities, and same-store occupancy was 89.7% against 86.7%.
- Net income is still a loss. Q3 2026 net loss was $5.6 million. On an unaudited pro forma basis, which assumes the acquisitions were owned all period, the nine months show a net loss of $95.6 million against FFO as Adjusted of $240.0 million, because depreciation is large and FFO adds it back.
- The external manager charges $10.0 million a year plus 0.5% of the gross book value of acquisitions, which the prospectus puts at $25.1 million a year now; the agreement runs to March 23, 2029, and ending it costs three times the trailing 12-month fee. Dividend: $0.57 a share a year, intended to be held through March 2027.
CSV · 113 rows
Janus Living (JAN): four stock offerings, Healthpeak ownership and lock-ups, portfolio, Q3 2026 results, debt, management fee and dividend
113 rows from the 424B4 of November 5, 2026, the Q3 2026 10-Q, the 8-Ks of September 17 and November 6, 2026, the earlier prospectuses and Healthpeak's Schedule 13G. Form and accession number on every row.
The date matters: November 5 was the fourth sale, not the IPO
The filings separate four events. The IPO prospectus is dated March 19, 2026 and priced 42,000,000 shares at $20.00; the 10-Q says the company completed its initial public offering on March 23, 2026 and issued 48,300,000 shares including the option, for $966 million gross. Each later sale was priced below the last reported trade, by 1.8% in June, 3.9% in August and 5.2% in November (our arithmetic from the cover pages).
| Sale | Offering price | Last reported sale before pricing | Shares at closing (with option) | Gross proceeds | Source |
|---|---|---|---|---|---|
| IPO, March 2026 | $20.00 | none (first listing) | 48,300,000 (42,000,000 base) | $966 million | 424B4 0001104659-26-032901; 10-Q 0001628280-26-069530 |
| Follow-on, June 2026 | $25.00 | $25.45 (June 2, 2026) | 28,750,000 (25,000,000 base) | $719 million | 424B4 0001104659-26-070188; 10-Q |
| Follow-on, August 2026 | $29.00 | $30.18 (August 10, 2026) | 18,400,000 (16,000,000 base) | $534 million | 424B4 0001104659-26-094083; 8-K 0001104659-26-094947 |
| Follow-on, November 2026 | $28.50 | $30.07 (November 4, 2026) | 30,187,500 (26,250,000 base) | about $860.3 million (our arithmetic) | 424B4 0001104659-26-123373; 8-K 0001104659-26-123853 |
The November underwriting discount is $1.06875 a share, 3.75% of the price (our arithmetic), and the 424B4 estimates net proceeds of about $719 million before the option and $827 million with it. The underwriting agreement is dated November 4, 2026. The 8-K says the sale was made under registration statement File No. 333-299816 and a second statement, File No. 333-299833, filed under Rule 462(b), and that the underwriters bought all 3,937,500 option shares.
The price did not follow a straight line: $28.50 is 42.5% above the IPO price and 1.7% below August's $29.00 (our arithmetic). Those are offering prices. This page does not say where the shares will trade.
Who owns Janus after November: Healthpeak sold nothing
Janus is not a spin-off. In each of the four sales the prospectus says all shares offered are “being sold by us”, meaning Janus, not Healthpeak, and none were handed out to Healthpeak's own shareholders. Healthpeak put its senior housing business into Janus through what the prospectus calls the formation transactions, kept the majority and became the external manager. The prospectus calls Janus “a pure-play senior housing REIT and the only U.S. publicly traded REIT whose portfolio is owned and operated under RIDEA or similar structures”, and says it is “externally managed and advised by Healthpeak Investment Management, LLC”, an indirect Healthpeak subsidiary.
| Holder or item | What the filing says | Source |
|---|---|---|
| Healthpeak Class A-1 shares | 138,816,246, which is 53.3% of Class A-1 after the base offering (52.5% if the option is exercised in full) | 424B4, principal stockholders and lock-up sections |
| Healthpeak Class A-2 shares | 75,917,780, 100% of the class. They carry votes, not dividends: one vote for each operating unit Healthpeak holds | 424B4 |
| Healthpeak voting power | 63.8% after the base offering | 424B4 |
| Healthpeak at March 31, 2026 | 214,734,026 shares and units, reported as 81.6% | Schedule 13G filed May 14, 2026, 0001104659-26-061302 |
| Healthpeak after the November closing | about 63.1% of shares plus units: 214,734,026 of 340,478,276 (our arithmetic; 234,372,996 plus 30,187,500 Class A-1 plus 75,917,780 units) | 10-Q cover, 8-K and 424B4 |
| Public holders of Class A-1 | all other Class A-1 shares, about 125.7 million of 264.6 million after closing (our arithmetic) | 10-Q cover, 424B4 |
| Officers | “All of our officers are employees of Healthpeak or its affiliates.” Janus has no employees of its own | 424B4 |
| Controlled company | Healthpeak affiliates own a majority of the voting power of shares eligible to vote for directors, so Janus is a controlled company under NYSE rules | 424B4 |
The operating units matter for dilution. Common units are redeemable for cash or, at Janus's election, for Class A-1 shares one for one, and units held by Healthpeak can be redeemed at any time. Other unit holders wait 14 months. If Healthpeak exchanged all 75,917,780 units, Class A-1 shares would rise by that number and the public's slice of the Class A-1 class would shrink, although the public's share of shares plus units would not change.
What Healthpeak keeps, and when it can sell. Healthpeak, the manager, officers, directors and substantially all other existing holders agreed not to sell for 365 days after March 19, 2026, which is until March 19, 2027 (our arithmetic), without the written consent of BofA Securities and J.P. Morgan; independent directors not affiliated with Healthpeak have 180 days for the IPO, 90 days after the August sale and 90 days after the November prospectus, which runs to about February 2, 2027 (our arithmetic). The underwriters state that they have no present intent or arrangement to release any shares subject to a lock-up. Healthpeak has demand and piggyback registration rights covering 214,734,026 shares, including a right to demand that Janus sell shares for its own account and use the proceeds to buy Healthpeak's shares or units. On our reading that is a route by which Healthpeak could be paid out later; no such sale is announced.
What Janus owns
At September 30, 2026 Janus had 74 senior housing communities with 15,256 units, in 19 states, with Florida and Texas holding 57% of units. Fifteen are life plan communities (7,029 units, 46.1% of units, our arithmetic); the other 59 (8,227 units) are mostly independent living. All are owned and run under RIDEA or similar structures, which means Janus receives the property's operating cash flow and pays an operator a management fee, instead of collecting a fixed rent.
| Portfolio item | Figure at September 30, 2026 | Source |
|---|---|---|
| Communities | 74 | 424B4 |
| Units | 15,256 (16,277 pro forma for the seven communities bought after quarter end and one probable purchase) | 424B4 |
| States | 19; Florida and Texas 57% of units | 424B4 |
| Life plan communities | 15 communities, 7,029 units | 424B4 |
| Other communities | 59 communities, 8,227 units | 424B4 |
| Largest operators | LCS manages 15 communities and Sunrise Senior Living Management manages 2; eleven additional operators signed in 2026 | 424B4 |
| Bought in 2026 through September | 41 communities for $2.26 billion | 10-Q |
| Bought after September 30 | seven communities for $432 million, plus one property for $23 million the prospectus calls probable, not yet closed | 424B4 |
| Total for the joint venture buyout and all acquisitions | $3.0 billion | 424B4 |
Operators are one risk the prospectus names: Janus does not run the buildings. The prospectus describes a $2.5 million termination fee Janus had to pay Brookdale Senior Living when 18 properties moved to new managers after the joint venture buyout. Eleven new operators in one year is a number to watch against the occupancy line below.
Q3 2026 numbers
Resident fees and services were $268.3 million in Q3 2026 against $150.5 million a year earlier, up 78.3% (our arithmetic). Most of that is acquisitions: the same-store group of 15 communities grew Adjusted NOI 25.9%, from $36.6 million to $46.1 million, on average occupancy of 89.7% against 86.7% and revenue per occupied unit of $8,726 a month against $8,193. The total portfolio of 74 communities had average occupancy of 86.5% (85.8% a year earlier) and revenue per occupied unit of $7,421 a month, down from $7,588.
| Measure (USD thousand) | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 | Nine months 2026 pro forma |
|---|---|---|---|---|---|
| Resident fees and services | 268,300 | 150,458 | 685,101 | 448,240 | 933,773 |
| NOI | 74,881 | 41,835 | 189,046 | 129,347 | 269,501 |
| Adjusted NOI | 75,599 | 41,813 | 189,764 | 128,448 | 270,219 |
| Nareit FFO | 73,074 | 37,069 | 172,262 | 105,883 | 223,470 |
| FFO as Adjusted | 75,848 | 36,808 | 189,699 | 109,830 | 239,995 |
| Net income (loss) | (5,608) | 1,412 | 37,124 | (3,268) | (95,624) |
Three cautions from the same documents. First, the history before March 2026 is a combination of assets Healthpeak owned and includes allocated Healthpeak costs; the prospectus says it is not what a stand-alone company would have reported. Second, the nine-month 2026 net income of $37.1 million includes a gain on change of control from the joint venture buyout in January 2026, which Nareit FFO excludes. Third, the pro forma column assumes the acquisitions were owned from January 1, 2025, and that net loss of $95.6 million sits beside $240.0 million of FFO as Adjusted. A rough per-share view: Q3 FFO as Adjusted of $75.8 million over 225,973 thousand weighted Class A-1 shares plus 75,918 thousand units is about $0.25 a share (our arithmetic); because the weighted count is lower than the count at quarter end, the real per-share figure is lower.
Cash, debt and what the money is for
Janus had $338.1 million of cash and no debt on September 30, 2026; the pro forma figure after the base November sale is $600.4 million. It then drew on its revolver: $100 million was outstanding on November 3, 2026 at SOFR plus 1.05% (4.99% that day), used in part for October acquisitions and for distributions. The prospectus says the money from this sale goes to acquisitions and investments, to repay the revolver and to general purposes, and that Janus has no binding commitment for any uncompleted acquisition other than the one probable purchase. Affiliates of some underwriters are lenders under the revolver and receive their share of the repayment.
| Facility or balance | Figure | Source |
|---|---|---|
| Revolving credit facility | $1.25 billion, raised from $500 million on September 17, 2026; maturity March 2030 | 8-K 0001104659-26-108578; 10-Q |
| Accordion | up to $1.75 billion in total with incremental term loans | 8-K 0001104659-26-108578 |
| Delayed draw term loan | $100 million facility terminated before any draw | 8-K 0001104659-26-108578 |
| Borrowed at September 30, 2026 | none | 10-Q |
| Borrowed at November 3, 2026 | $100 million at 4.99% | 424B4 |
| Cash, September 30, 2026 | $338.1 million; $600.4 million pro forma after the base November sale | 424B4 |
| Interest earned on invested cash, nine months | $19 million ($8 million in Q3) | 10-Q |
The cash earned $19 million of interest in nine months. That is income from the offering proceeds sitting unspent, and it shrinks when the money is invested in buildings.
What Janus pays Healthpeak
The manager gets a base fee of $10.0 million a year, plus or minus 0.5% a year of the gross book value of each acquisition, disposition or large capital project since January 1, 2026. After the joint venture buyout and the acquisitions the prospectus says the fee rises by $15.1 million to $25.1 million a year, $2.1 million a month. Against pro forma 2025 NOI of $328.5 million that is 7.6% (our arithmetic; NOI is before the fee). The related-party fee in Q3 2026 general and administrative expense was $3.8 million, and Janus separately incurred $13 million of operator management fees in the quarter on consolidated assets.
| Term | What the prospectus says |
|---|---|
| Base fee | $10.0 million a year, adjusted by 0.5% of gross book value of acquisitions (less on larger sizes of gross book value) and dispositions; stock compensation on certain awards reduces it |
| Fee now | $25.1 million a year, $2.1 million a month, after the acquisitions to date |
| Term | initial term expiring March 23, 2029, then one-year renewals |
| Ending it without cause | needs a majority of independent directors not affiliated with Healthpeak, then a majority of all votes at a stockholder meeting; Janus then pays three times the fee earned in the prior 12 months |
| Nature of the relationship | The prospectus calls the manager's relationship with Janus “contractual” |
| Janus's staff | “All of our officers are employees of Healthpeak or its affiliates” |
With a termination fee of three times a fee that grows with every acquisition, and Healthpeak holding 63% of the votes, the removal route runs through the party being removed. This is a description of the terms, not a prediction.
Dividend
Janus declared $0.0475 a share each month for the fourth quarter of 2026 on September 11, 2026, $0.57 a year. Record dates are November 12 and December 18, 2026, paid November 23 and December 29, 2026; buyers in the November sale who held at the record dates receive them. The prospectus says Janus intends to keep the rate through the end of March 2027 unless results or other factors differ materially. At the $28.50 offering price that is a 2.0% yield (our arithmetic; an offering price, not a market price). Using Q3 2026 FFO as Adjusted of about $0.25 a share (our arithmetic), the $0.1425 declared for the quarter is about 57% of it.
What is new compared with our Healthpeak page
Our page on Healthpeak (DOC) was written on October 19, 2026 from the Q2 filings. Since then Janus has filed three documents that change parts of it.
| Item | Healthpeak page, October 19, 2026 | Janus documents, November 2026 |
|---|---|---|
| Healthpeak's stake | 73.6% at June 30, 2026; outside holders 26.4% | about 63.1% of shares plus units after the November closing, so outside holders hold about 36.9% (our arithmetic); the August and November sales added about 48.6 million shares (our arithmetic) |
| Offerings listed | March IPO and June follow-on | plus August (18,400,000 at $29.00) and November (30,187,500 at $28.50) |
| Janus debt | $500 million revolver and $100 million term loan, undrawn, no debt on August 3, 2026 | $1.25 billion revolver, term loan terminated, $100 million drawn on November 3, 2026 |
| Communities | 41 communities in Healthpeak's senior housing segment | 74 communities and 15,256 units at September 30, 2026 in Janus |
| Janus's cash | $558 million at August 3, 2026 | $338.1 million at September 30, 2026 |
Peers: Welltower (WELL) and Ventas (VTR) also report senior housing operating results. Funds that hold Janus are covered in our REIT ETF holdings page.
What a holder can do
- Separate Janus from Healthpeak. Healthpeak owns about 63% of Janus; a Janus holder shares the earnings with Healthpeak, which also collects the manager's fee. A holder of both is counting the same buildings twice.
- Read the lock-up dates. The date to put in a calendar is March 19, 2027, for Healthpeak, the manager and officers; the registration rights show the route to a later sale.
- Watch what the proceeds buy. The use of proceeds names acquisitions with no binding agreement but one. Occupancy of 86.5% in the total portfolio against 89.7% in the same-store group is the number to compare in the next 10-K.
- Look at the fee. $25.1 million a year, growing with each purchase, is paid before shareholders see a dollar of FFO, so acquisitions raise the fee as well as the earnings.
- Size the position. If JAN, DOC and other healthcare REITs together are a large part of your portfolio, one conversation with a qualified adviser about how they fit may be worth having.
This is analysis of public documents, not investment, legal or tax advice.
FAQ
Figures are from Janus Living, Inc. (SEC CIK 2100805) filings read on EDGAR on November 20, 2026: Form 424B4 of November 5, 2026 (accession 0001104659-26-123373); Form 8-K of November 6, 2026 (0001104659-26-123853); Form 10-Q for the quarter ended September 30, 2026 (0001628280-26-069530); Form 8-K of September 17, 2026 (0001104659-26-108578); Forms 424B4 of March 23, June 3 and August 11, 2026 (0001104659-26-032901, 0001104659-26-070188, 0001104659-26-094083) and Forms 8-K of June 4 and August 12, 2026 (0001104659-26-070511, 0001104659-26-094947); Schedule 13G filed by Healthpeak Properties, Inc. on May 14, 2026 (0001104659-26-061302). Where we calculate, the text says "our arithmetic".